Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Program for United States of America: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD); Specific Therapeutic Program for Czech Republic: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD)

NCT06955793 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06955793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06955793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Program for United States of America: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD); Specific Therapeutic Program for Czech Republic: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD)
Lead sponsor
Takeda
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pidd)